⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30594991 | 0.98 | — | — | |
| SCHEMBL6058542 | 0.67 | — | — | |
| SCHEMBL277317 | 0.67 | — | — | |
| SCHEMBL15178398 | 0.67 | CA1 (0.33) | — | |
| SCHEMBL12706223 | 0.63 | — | — | |
| SCHEMBL194443 | 0.62 | — | — | |
| SCHEMBL14752566 | 0.62 | — | — | |
| SCHEMBL2240829 | 0.62 | — | — | |
| SCHEMBL5308708 | 0.62 | — | — | |
| SCHEMBL14863740 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4543878-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043148-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
| EP-4308562-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2001068603-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL-MYERS SQUIBB CO. (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-0500653-A4 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST INC (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0561841-B1 | METHOD OF PREPARING FORMYLTETRAHYDROPYRANS | BASF AG (DE) | 1995-08-23 | — | — | EP | disclosed |
| EP-0561841-A1 | METHOD OF PREPARING FORMYLTETRAHYDROPYRANS. | BASF AG (DE) | 1993-09-29 | — | — | EP | disclosed |
| EP-0500653-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992010488-A1 | METHOD OF PREPARING FORMYLTETRAHYDROPYRANS | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-25 | — | — | WO | disclosed |
| WO-1991006548-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-5008270-A | 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same | BIOCRYST, INC. (US) | 1991-04-16 | — | — | US | disclosed |